Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
CERAMENT™| Bone Void Filler Device Registry
NCT04244942
Recruiting
A device registry to compile data on the performance of CERAMENT BONE VOID FILLER in normal use.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: HonorHealth, Scottsdale, Arizona
Conditions: Orthopedic Disorder
Register for Updates
e-HERO: Ending the HIV Epidemic in Rural Oklahoma
NCT05664802
Recruiting
The goal of this study is to increase HIV and syphilis testing and linkage to care, increase condom use, and promote PrEP uptake among sexual minority men (SMM) and American Indian (AI) men in rural Oklahoma, a state that is an Ending the HIV Epidemic (EHE) priority state. The proposed supplement aims to: refine our preliminary intervention strategy in partnership with a Community Advisory Board (CAB) and rural peer mentors, and to assess feasibility, acceptability, and preliminary impact of the... Read More
Gender:
MALE
Ages:
Between 17 years and 29 years
Trial Updated:
03/19/2024
Locations: Northern Arizona University, Flagstaff, Arizona
Conditions: Human Immunodeficiency Virus (HIV)
Register for Updates
Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions
NCT04905160
Recruiting
Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Multiple Locations, Phoenix, Arizona
Conditions: Heart Failure, ADHF, Acute MI
Register for Updates
COVID-19 Risk Assessment for Hospitalization Outcomes and Epidemiology Efficacy
NCT04678193
Recruiting
Researchers are creating real-time epidemiology registry to evaluate the efficacy of COVID-19 subject risk assessment scores based on recording of symptoms, biomarkers, chronic illness and mental health assessments with digital technology using wearables and mobile app tools. Researchers aim to study in Phase 1, epidemiological variations in COVID-19 presentation in both PCR positive and negative subjects in the registry. Assessment of variables, predictive modeling of variables that impact seve... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2024
Locations: Multiple Locations, Phoenix, Arizona
Conditions: Covid19
Register for Updates
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
NCT06322693
Recruiting
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022. The study will be conducted in 2 parts with Part 1 consisting of dose escalation and Part 2 dose expansion. Part 1 will determine the recommended Phase 2 dose (RP2D) of TSR-022 and Part 2 will evaluate the antitumor activity of TSR-022 in combination with TSR-042 or docetaxel and as monotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: GSK Investigational Site, Goodyear, Arizona
Conditions: Neoplasms
Register for Updates
Microbiota Transfer Therapy for Children and Adults With Both Pitt Hopkins Syndrome and Gastrointestinal Disorders
NCT06321796
Recruiting
The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating patients with Pitt-Hopkins Syndrome (PTHS) and gastrointestinal problems (constipation, bloating, abdominal pain). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by 1 day of bowel cleanse using magnesium citrate, followed by 4 days of high dose MTP-101P with an antacid, followed by 12 weeks of a lower maintenance dose of MTP-101P with an antacid.
Gender:
ALL
Ages:
Between 5 years and 55 years
Trial Updated:
03/14/2024
Locations: Autism/Asperger's Research Group at Arizona State University, Tempe, Arizona
Conditions: Pitt Hopkins Syndrome
Register for Updates
LOWER: Lomitapide Observational Worldwide Evaluation Registry
NCT02135705
Recruiting
This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.
Gender:
ALL
Ages:
All
Trial Updated:
03/11/2024
Locations: Northern Arizona Healthcare, Cottonwood, Arizona
Conditions: Homozygous Familial Hypercholesterolemia
Register for Updates
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
NCT05442567
Recruiting
The study is an extension of two parent studies (MLN0002-3024 \[NCT04779307\] and MLN0002-3025 \[NCT04779320\]). Participants must have participated in one of the previous studies. The purpose of this study is to collect the long-term safety of vedolizumab in children with UC or CD.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
03/05/2024
Locations: Phoenix Childrens Hospital -1919 E Thompson Rd, Phoenix, Arizona
Conditions: Ulcerative Colitis, Crohn's Disease
Register for Updates
Prospective Evaluation of Complex Adult Spinal Deformity (CAD) Treated With Minimally Invasive Surgery
NCT04885244
Recruiting
Evaluate surgical treatment outcomes and identify best practice guidelines for complex adult spinal deformity (ASD) patients treated with minimally invasive approach, including radiographic and clinical outcomes, surgical and postoperative complications, risk factors for and revision surgery rates, and the role of standard work to improve patient outcomes and reduce surgical and postoperative complications.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/04/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Adult Spinal Deformity, Scoliosis, Kyphosis, Sagittal Imbalance
Register for Updates
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia
NCT01158807
Recruiting
This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research. The consortium research focuses on brain blood vessel malformations in three different rare diseases. The focus of this specific study is on Hemorrhagic Telangiectasia (HHT). HHT is a condition characterized by blood vessel malformations, called telangiectasia and arteriovenous malformations (AVMs), occurring in... Read More
Gender:
ALL
Ages:
All
Trial Updated:
03/04/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona
Conditions: Hereditary Hemorrhagic Telangiectasia
Register for Updates
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
NCT01574053
Recruiting
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and b... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/26/2024
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Huntington's Disease
Register for Updates
Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration
NCT05657301
Recruiting
VAN-2201 is Phase I clinical trial to assess the safety and tolerability of KH631 in subjects with neovascular AMD. KH631 is gene therapy designed to deliver a protein which targets and blocks VEGF via an adeno-associated viral vector. The standard of care for patients with neovascular AMD are anti-VEGF treaments, which have demonstrated improvement in vision and reduction in fluid. A one time placement of a product which inhibits VEGF has the potential to reduce the patient burden of regular in... Read More
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
02/23/2024
Locations: Kanghong Investigative Site, Phoenix, Arizona
Conditions: Age-Related Macular Degeneration
Register for Updates